Matches in SemOpenAlex for { <https://semopenalex.org/work/W3130687955> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W3130687955 endingPage "12" @default.
- W3130687955 startingPage "PS13" @default.
- W3130687955 abstract "Abstract Background: Apatinib, a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR2), has demonstrated a promising efficacy in patients with metastatic breast cancer. For triple-negative and HER2-positive subtypes, increasing the pathological complete response (pCR) of neoadjuvant therapy may benefit their clinical outcomes. Here, we assessed whether the combination of Apatinib with neoadjuvant chemotherapy elevate the pCR rate in locally advanced breast cancer. Method: In this multicenter, open-label trial, we randomized 53 patients into TP neoadjuvant chemotherapy (docetaxel 75 mg/m2 or nab-paclitaxel 260 mg/m2 or paclitaxel liposome 175 mg/m2 day 1, and carboplatin AUC=6 or cisplatin 75 mg/m2 or lobaplatin 30 mg/m2 day 1), or combined with apatinib (500mg day 1-21) . Trastuzumab was added to neoadjuvant therapy in HER2-positive subtype. Six cycles were repeated every 3 weeks. Results: In total patients with stage IIb-IIIc triple-negative and HER2-positive breast cancer, the addition of apatinib to TP neoadjuvant chemotherapy (Apa+TP) significantly increased the pCR rate (70.8%, 17/24), compared with TP along (41.4%, 12/29), P=0.032. When separating patients into triple-negative (Apa+TP 66.7% (8/12) vs. TP 42.9% (3/7)) and HER2-positve (Apa+TP 75% (9/12) vs. TP 40.9% (9/22)) subtypes, the effect of apatinib on pCR was also improved though no significant differences were found (P=0.377; P=0.080 separately) compared with control group. The most common Grade 3-4 adverse events (AE) included hypertension (Apa+TP 12.5% vs. TP 0%, P=0.173), hand-foot syndrome (Apa+TP 8.3% vs. TP 0%, P=0.389) and erythra (Apa+TP 4.2% vs. TP 0%, P=0.924). No significant differences of toxic effects were found between Apa+TP and control group. Conclusion: Apatinib combined with TP neoadjuvant chemotherapy significantly increased the pCR rate in patients with locally advanced triple-negative and HER2-positive breast cancer, indicating an applicable strategy in the future. EfficacyTriple-negative breast cancer efficacyHer2-positive breast cancer efficacySafety Citation Format: Yunjiang Liu, Xiangmei Zhang, Li Wang, Miao Cao, Shuo Zhang, Hui Zhang, Yarong Zhou, Jintian Wang. Apatinib combined with taxanes and platinum neoadjuvant chemotherapy for patients with triple-negative and HER2-positive breast cancer: A multicenter, randomized, open-label, phase II trial [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS13-12." @default.
- W3130687955 created "2021-03-01" @default.
- W3130687955 creator A5003759585 @default.
- W3130687955 creator A5010070743 @default.
- W3130687955 creator A5012278873 @default.
- W3130687955 creator A5018688163 @default.
- W3130687955 creator A5056541931 @default.
- W3130687955 creator A5060270213 @default.
- W3130687955 creator A5082924617 @default.
- W3130687955 creator A5089695678 @default.
- W3130687955 date "2021-02-15" @default.
- W3130687955 modified "2023-09-22" @default.
- W3130687955 title "Abstract PS13-12: Apatinib combined with taxanes and platinum neoadjuvant chemotherapy for patients with triple-negative and HER2-positive breast cancer: A multicenter, randomized, open-label, phase II trial" @default.
- W3130687955 doi "https://doi.org/10.1158/1538-7445.sabcs20-ps13-12" @default.
- W3130687955 hasPublicationYear "2021" @default.
- W3130687955 type Work @default.
- W3130687955 sameAs 3130687955 @default.
- W3130687955 citedByCount "0" @default.
- W3130687955 crossrefType "journal-article" @default.
- W3130687955 hasAuthorship W3130687955A5003759585 @default.
- W3130687955 hasAuthorship W3130687955A5010070743 @default.
- W3130687955 hasAuthorship W3130687955A5012278873 @default.
- W3130687955 hasAuthorship W3130687955A5018688163 @default.
- W3130687955 hasAuthorship W3130687955A5056541931 @default.
- W3130687955 hasAuthorship W3130687955A5060270213 @default.
- W3130687955 hasAuthorship W3130687955A5082924617 @default.
- W3130687955 hasAuthorship W3130687955A5089695678 @default.
- W3130687955 hasConcept C121608353 @default.
- W3130687955 hasConcept C126322002 @default.
- W3130687955 hasConcept C143998085 @default.
- W3130687955 hasConcept C2776694085 @default.
- W3130687955 hasConcept C2777292972 @default.
- W3130687955 hasConcept C2778239845 @default.
- W3130687955 hasConcept C2778292576 @default.
- W3130687955 hasConcept C2779786085 @default.
- W3130687955 hasConcept C2780110267 @default.
- W3130687955 hasConcept C2780668389 @default.
- W3130687955 hasConcept C2781190966 @default.
- W3130687955 hasConcept C2781451048 @default.
- W3130687955 hasConcept C31760486 @default.
- W3130687955 hasConcept C530470458 @default.
- W3130687955 hasConcept C71924100 @default.
- W3130687955 hasConcept C90924648 @default.
- W3130687955 hasConceptScore W3130687955C121608353 @default.
- W3130687955 hasConceptScore W3130687955C126322002 @default.
- W3130687955 hasConceptScore W3130687955C143998085 @default.
- W3130687955 hasConceptScore W3130687955C2776694085 @default.
- W3130687955 hasConceptScore W3130687955C2777292972 @default.
- W3130687955 hasConceptScore W3130687955C2778239845 @default.
- W3130687955 hasConceptScore W3130687955C2778292576 @default.
- W3130687955 hasConceptScore W3130687955C2779786085 @default.
- W3130687955 hasConceptScore W3130687955C2780110267 @default.
- W3130687955 hasConceptScore W3130687955C2780668389 @default.
- W3130687955 hasConceptScore W3130687955C2781190966 @default.
- W3130687955 hasConceptScore W3130687955C2781451048 @default.
- W3130687955 hasConceptScore W3130687955C31760486 @default.
- W3130687955 hasConceptScore W3130687955C530470458 @default.
- W3130687955 hasConceptScore W3130687955C71924100 @default.
- W3130687955 hasConceptScore W3130687955C90924648 @default.
- W3130687955 hasIssue "4_Supplement" @default.
- W3130687955 hasLocation W31306879551 @default.
- W3130687955 hasOpenAccess W3130687955 @default.
- W3130687955 hasPrimaryLocation W31306879551 @default.
- W3130687955 hasRelatedWork W2004818507 @default.
- W3130687955 hasRelatedWork W2066652032 @default.
- W3130687955 hasRelatedWork W2085791731 @default.
- W3130687955 hasRelatedWork W2091007248 @default.
- W3130687955 hasRelatedWork W2094661349 @default.
- W3130687955 hasRelatedWork W2100029565 @default.
- W3130687955 hasRelatedWork W2389825807 @default.
- W3130687955 hasRelatedWork W2591111963 @default.
- W3130687955 hasRelatedWork W4232824905 @default.
- W3130687955 hasRelatedWork W4361932620 @default.
- W3130687955 hasVolume "81" @default.
- W3130687955 isParatext "false" @default.
- W3130687955 isRetracted "false" @default.
- W3130687955 magId "3130687955" @default.
- W3130687955 workType "article" @default.